Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Chromadex Corp CS
(NQ:
CDXC
)
3.400
+0.450 (+15.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
461,357
Open
2.950
Bid (Size)
3.350 (2)
Ask (Size)
3.430 (5)
Prev. Close
2.950
Today's Range
2.940 - 3.440
52wk Range
1.250 - 4.650
Shares Outstanding
68,196,526
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
April 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
March 26, 2024
From
ChromaDex Corporation
Via
Business Wire
Performance
YTD
+137.76%
+137.76%
1 Month
-10.29%
-10.29%
3 Month
+150.00%
+150.00%
6 Month
+159.54%
+159.54%
1 Year
+148.18%
+148.18%
More News
Read More
CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023
March 06, 2024
Via
InvestorPlace
Earnings Preview For ChromaDex
March 05, 2024
Via
Benzinga
ChromaDex: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
Earnings Outlook For ChromaDex
November 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 18, 2024
Via
Benzinga
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
March 06, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
February 21, 2024
From
ChromaDex Corporation
Via
Business Wire
Earnings Scheduled For March 6, 2024
March 06, 2024
Via
Benzinga
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
February 05, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
January 26, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
December 20, 2023
From
ChromaDex Corporation
Via
Business Wire
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
November 30, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
November 09, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
November 08, 2023
From
ChromaDex Corporation
Via
Business Wire
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
November 15, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
November 01, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 31, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
October 26, 2023
From
ChromaDex Corporation
Via
Business Wire
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
October 02, 2023
From
ChromaDex Corporation
Via
Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
August 24, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
August 09, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
August 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
August 07, 2023
From
ChromaDex Corporation
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.